摘要
目的评价生血宝合剂治疗慢性肾脏病非透析患者肾性贫血(Renal anemia,RA)的临床疗效与安全性。方法选取九江市中医院肾病科2018年4月—2020年5月收治的慢性肾脏病非透析贫血住院患者,随机分为对照组(53例)和治疗组(53例)。对照组采用常规促红素、补铁等治疗,治疗组在对照组基础上给予生血宝合剂,连续治疗2个月。分别检测治疗前后血红蛋白、红细胞压积、肾功能、血清白蛋白、IL-6、CRP的改变,评估中医证候积分。结果治疗组总有效率88.68%(47/53),对照组总有效率58.49%(31/53),2组差异具有统计学意义(P<0.05)。治疗组血红蛋白、红细胞压积、血清肌酐、血清白蛋白、IL-6、CRP改善较对照组更为明显(P<0.05)。治疗组中医证候积分较对照组低(P<0.05)。治疗组不良反应总发生率显著低于对照组(P<0.05)。结论生血宝合剂治疗RA具有显著的临床疗效,值得进一步推广。
Objective To evaluate the clinical efficacy and safety of Shengxuebao mixture in the treatment of renal anemia(RA)in non-dialysis patients with chronic kidney disease.Methods Inpatients with CKD non-dialysis anemia in the department of nephrology of Jiujiang Hospital of Traditional Chinese Medicine from April 2018 to May 2020 were selected and randomly divided into a control group of 53 cases and a treatment group of 53 cases.The control group was treated with conventional erythropoietin and iron supplementation,and the treatment group was given Shengxuebao mixture on the basis of the control group for 2 months of continuous treatment.The changes of hemoglobin,hematocrit,renal function,serum albumin,IL6,and CRP before and after treatment were detected respectively,and the TCM syndrome score was evaluated.Results The total effective rate of the treatment group was 88.68%,and the total effective rate of the control group was 58.49%.The difference was statistically significant(P<0.05).The serum of the hemoglobin,hematocrit,serum creatinine,serum albumin,IL6,and CRP of the treatment group improved compared with the control group(P<0.05).The scores of TCM syndromes in the treatment group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the treatment group was significantly lower than that in the control group(P<0.05).Conclusion Shengxuebao mixture has significantly clinical effect in treating RA and is worthy of further promotion.
作者
魏林
卢海群
傅奕
陈帮明
吴兆东
付义
刘永芳
WEI Lin;LU Haiqun;FU Yi;CHEN Bangming;WU Zhaodong;FU Yi;LIU Yongfang(Department of Nephrology,Jiujiang Hospital of Traditional Chinese Medicine,Jiangxi Province,Jiujiang 332000,China)
出处
《中国中医药现代远程教育》
2020年第23期69-72,共4页
Chinese Medicine Modern Distance Education of China
基金
江西省科技厅一般项目【No.S2016SFYBG0294】
江西省卫生健康委科技计划【No.20204305】
江西省中医药科研计划【No.2019A395】。
关键词
生血宝合剂
慢性肾脏病
肾性贫血
临床疗效
安全性评价
虚劳
Shengxuebao mixture
chronic kidney disease
renal anemia
clinical effect
safety evaluation
consumptive disease